Potential Benefits of Lenvatinib in Renal Cell Carcinoma
Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.
Naomi B. Haas, MD, medical oncologist, director of the Prostate and Kidney cancer Program and professor of Medicine at the Hospital of the University of Pennsylvania, discusses the potential benefits of lenvatinib (Lenvima) for the treatment of renal cell carcinoma (RCC).
According to Haas, there are phase 2 studies ongoing to investigate the benefit of lenvatinib in patients with RCC. One potential benefit is that lenvatinib may augment its activity with immune checkpoint inhibitors. Additionally, some data suggests that it helps to stimulate regulatory T cells and prevent T-cell exhaustion. Haas says that these are the 2 reasons why immune checkpoint inhibitors sometimes do not work in this patient population.
0:08 | There are certainly phase 2 initiatives that are being done to understand the benefit in patients. Lenvatinib is an interesting drug because it probably also has some immunologic aspects that can augment its activity with immune checkpoint inhibitors. So, there's some data to suggest that it might help stimulate regulatory T cells and it might be a way to prevent T-cell exhaustion, which are 2 reasons that immune checkpoint inhibitors sometimes don't work in patients. So, I think it's a very useful approach and I feel encouraged about that.
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Ornstein Advises on Starting Dose and Management of Lenvatinib in RCC
April 21st 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient treated with lenvatinib plus pembrolizumab for advanced renal cell carcinoma.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
